Delving into the Latest Updates on Biofilm Pharma with Synapse

Overview

Tags

Infectious Diseases

Skin and Musculoskeletal Diseases

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	3
Endocrinology and Metabolic Disease	2
Nervous System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	3

Antimicrobial susceptibility tests (AST) are based on the minimal inhibitory concentration (MIC), the method used worldwide to guide antimicrobial therapy. Despite its relevance in correctly predicting clinical outcome for most acute infections, this approach is misleading for multiple clinical cases in which pathogens do not grow rapidly, uniformly or with physical protection. This behaviour, named 'metabolic evasion' (ME), enables bacteria to survive antimicrobials. ME can result from different, and sometimes combined, bacterial mechanisms such as biofilms, intracellular growth, persisters or dormancy. We discuss how ME can influence the MIC-based probability of target attainment. We identify clinical cases in which this approach is undermined by ME and propose a new approach that takes ME into account in order to improve patient management and the evaluation of innovative drugs.

100 Deals associated with Biofilm Pharma

Login to view more data

100 Translational Medicine associated with Biofilm Pharma

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BFP-101	Diabetic Foot More	Discovery
BFP-001	Staphylococcal Infections More	Discovery
BFP-002	Pulmonary Disease, Chronic Obstructive More	Discovery
BFPA-05	Staphylococcal Infections More	Pending